{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:26:12Z","timestamp":1790439972837,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T00:00:00Z","timestamp":1505433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T00:00:00Z","timestamp":1505433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ribavirin is a broad spectrum antiviral which inhibits Lassa virus (LASV) replication<jats:italic>in vitro<\/jats:italic>but exhibits a minor effect on viremia<jats:italic>in vivo<\/jats:italic>. However, ribavirin significantly improves the disease outcome when administered in combination with sub-optimal doses of favipiravir, a strong antiviral drug. The mechanisms explaining these conflicting findings have not been determined, so far. Here, we used an interdisciplinary approach combining mathematical models and experimental data in LASV-infected mice that were treated with ribavirin alone or in combination with the drug favipiravir to explore different putative mechanisms of action for ribavirin. We test four different hypotheses that have been previously suggested for ribavirin\u2019s mode of action: (i) acting as a mutagen, thereby limiting the infectivity of new virions; (ii) reducing viremia by impairing viral production; (iii) modulating cell damage, i.e., by reducing inflammation, and (iv) enhancing antiviral immunity. Our analysis indicates that enhancement of antiviral immunity, as well as effects on viral production or transmission are unlikely to be ribavirin\u2019s main mechanism mediating its antiviral effectiveness against LASV infection. Instead, the modeled viral kinetics suggest that the main mode of action of ribavirin is to protect infected cells from dying, possibly reducing the inflammatory response.<\/jats:p>","DOI":"10.1038\/s41598-017-10198-0","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T11:09:15Z","timestamp":1505128155000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Determining Ribavirin\u2019s mechanism of action against Lassa virus infection"],"prefix":"10.1038","volume":"7","author":[{"given":"Paola","family":"Carrillo-Bustamante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Huyen Tram","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Oestereich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-5482","authenticated-orcid":false,"given":"Jeremie","family":"Guedj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Graw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,15]]},"reference":[{"key":"10198_CR1","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.cell.2015.07.020","volume":"162","author":"KG Andersen","year":"2015","unstructured":"Andersen, K. G. et al. Clinical sequencing uncovers origins and evolution of Lassa virus. Cell 162, 738\u2013750 (2015).","journal-title":"Cell"},{"key":"10198_CR2","first-page":"75","volume":"262","author":"JB McCormick","year":"2002","unstructured":"McCormick, J. B. & Fisher-Hoch, S. B. Lassa fever. Current Topics in Microbiology and Immunology 262, 75\u2013109 (2002).","journal-title":"Current Topics in Microbiology and Immunology"},{"key":"10198_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/10408360490497456","volume":"41","author":"S G\u00fcnther","year":"2004","unstructured":"G\u00fcnther, S. & Lenz, O. Lassa virus. Critical Reviews in Clinical Laboratory Sciences 41, 339\u2013390 (2004).","journal-title":"Critical Reviews in Clinical Laboratory Sciences"},{"key":"10198_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJM198601023140104","volume":"314","author":"JB McCormick","year":"1986","unstructured":"McCormick, J. B. et al. Lassa fever. Effective therapy with ribavirin. The New England Journal of Medicine 314, 20\u201326 (1986).","journal-title":"Effective therapy with ribavirin. The New England Journal of Medicine"},{"key":"10198_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1126\/science.177.4050.705","volume":"177","author":"RW Sidwell","year":"1972","unstructured":"Sidwell, R. W. et al. Broad-Spectrum antiviral activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamide. Science 177, 705\u2013706 (1972).","journal-title":"Science"},{"key":"10198_CR6","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1073\/pnas.70.4.1174","volume":"70","author":"DG Streeter","year":"1973","unstructured":"Streeter, D. G. et al. Mechanism of action of 1\u2013D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agen. t. Proceedings of the National Academy of Sciences of the United States of America 70, 1174\u20131178 (1973).","journal-title":"t. Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10198_CR7","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1093\/infdis\/jiv522","volume":"213","author":"L Oestereich","year":"2016","unstructured":"Oestereich, L. et al. Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. The Journal of Infectious Diseases 213, 934\u2013938 (2016).","journal-title":"The Journal of Infectious Diseases"},{"key":"10198_CR8","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried, M. W. et al. Peginterferon Alfa-2a plus ribavirin for chronic Hepatitis C virus infection. The New England Journal of Medicine 347, 975\u2013982 (2002).","journal-title":"The New England Journal of Medicine"},{"key":"10198_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis, S. J. et al. Peginterferon-\u03b1 2a and Ribavirin Combination Therapy in Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dos. e. Annals of Internal Medicine 140, 346\u2013355 (2004).","journal-title":"e. Annals of Internal Medicine"},{"key":"10198_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/gutjnl-2012-303852","volume":"63","author":"Y Rotman","year":"2014","unstructured":"Rotman, Y. et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 63, 161\u2013169 (2014).","journal-title":"Gut"},{"key":"10198_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1053\/j.gastro.2010.03.037","volume":"139","author":"JJ Feld","year":"2010","unstructured":"Feld, J. J. et al. Ribavirin improves early responses to Peginterferon through improved Interferon signaling. Gastroenterology 139, 154\u2013162.e4 (2010).","journal-title":"Gastroenterology"},{"key":"10198_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.antiviral.2015.12.006","volume":"126","author":"JB Westover","year":"2016","unstructured":"Westover, J. B. et al. Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Research 126, 62\u201368 (2016).","journal-title":"Antiviral Research"},{"key":"10198_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002804","volume":"8","author":"L Oestereich","year":"2014","unstructured":"Oestereich, L. et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Neglected Tropical Diseases 8, e2804 (2014).","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"10198_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","volume":"104","author":"D Scharton","year":"2014","unstructured":"Scharton, D. et al. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antiviral Research 104, 84\u201392 (2014).","journal-title":"Antiviral Research"},{"key":"10198_CR15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1053\/jhep.2002.32672","volume":"35","author":"JYN Lau","year":"2002","unstructured":"Lau, J. Y. N., Tam, R. C., Liang, T. J. & Hong, Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35, 1002\u20131009 (2002).","journal-title":"Hepatology"},{"key":"10198_CR16","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/nature04082","volume":"436","author":"JJ Feld","year":"2005","unstructured":"Feld, J. J. & Hoofnagle, J. H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436, 967\u2013972 (2005).","journal-title":"Nature"},{"key":"10198_CR17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S0168-8278(99)80093-2","volume":"30","author":"RC Tam","year":"1999","unstructured":"Tam, R. C. et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. Journal of Hepatology 30, 376\u2013382 (1999).","journal-title":"Journal of Hepatology"},{"key":"10198_CR18","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/j.1478-3231.2008.01896.x","volume":"28","author":"WP Hofmann","year":"2008","unstructured":"Hofmann, W. P., Herrmann, E., Sarrazin, C. & Zeuzem, S. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver International 28, 1332\u20131343 (2008).","journal-title":"Liver International"},{"key":"10198_CR19","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1128\/JVI.02778-12","volume":"87","author":"J Dietz","year":"2013","unstructured":"Dietz, J. et al. Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients. Journal of Virology 87, 6172\u20136181 (2013).","journal-title":"Journal of Virology"},{"key":"10198_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s00109-001-0308-0","volume":"80","author":"S Crotty","year":"2002","unstructured":"Crotty, S., Cameron, C. & Andino, R. Ribavirin\u2019s antiviral mechanism of action: lethal mutagenesis? Journal of Molecular Medicine 80, 86\u201395 (2002).","journal-title":"Journal of Molecular Medicine"},{"key":"10198_CR21","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1136\/gutjnl-2015-311000","volume":"65","author":"D Todt","year":"2016","unstructured":"Todt, D. et al. In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut 65, 1733\u20131743 (2016).","journal-title":"Gut"},{"key":"10198_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/v8100283","volume":"8","author":"D Todt","year":"2016","unstructured":"Todt, D., Walter, S., Brown, R. J. P. & Steinmann, E. Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations. Viruses 8, 283 (2016).","journal-title":"Viruses"},{"key":"10198_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jhep.2016.05.002","volume":"65","author":"Y Debing","year":"2016","unstructured":"Debing, Y. et al. Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. Journal of Hepatology 65, 499\u2013508 (2016).","journal-title":"Journal of Hepatology"},{"key":"10198_CR24","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1128\/JVI.77.2.1092-1104.2003","volume":"77","author":"RE Lanford","year":"2003","unstructured":"Lanford, R. E. et al. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(I)-poly(C), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. Journal of Virology 77, 1092\u20131104 (2003).","journal-title":"Journal of Virology"},{"key":"10198_CR25","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0042-6822(03)00152-1","volume":"310","author":"SF Zhou","year":"2003","unstructured":"Zhou, S. F., Liu, R., Baroudy, B. M., Malcolm, B. A. & Reyes, G. R. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310, 333\u2013342 (2003).","journal-title":"Virology"},{"key":"10198_CR26","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1128\/JVI.79.3.1943-1947.2005","volume":"79","author":"P Leyssen","year":"2005","unstructured":"Leyssen, P., Balzarini, J., De Clercq, E. & Neyts, J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. Journal of Virology 79, 1943\u20131947 (2005).","journal-title":"Journal of Virology"},{"key":"10198_CR27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1128\/AAC.17.5.770","volume":"17","author":"JF Hruska","year":"1980","unstructured":"Hruska, J. F., Bernstein, J. M., Douglas, R. G. Jr. & Hall, C. B. Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrobial Agents and Chemotherapy 17, 770\u2013775 (1980).","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10198_CR28","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","volume":"49","author":"Y Furuta","year":"2005","unstructured":"Furuta, Y. et al. Mechanism of action of T-705 against influenza virus. Antimicrobial Agents and Chemotherapy 49, 981\u2013986 (2005).","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10198_CR29","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta, Y. et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Research 100, 446\u2013454 (2013).","journal-title":"Antiviral Research"},{"key":"10198_CR30","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns, M. P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. The Lancet 358, 958\u2013965 (2001).","journal-title":"The Lancet"},{"key":"10198_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1053\/j.gastro.2003.12.002","volume":"126","author":"J-M Pawlotsky","year":"2004","unstructured":"Pawlotsky, J.-M. et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126, 703\u2013714 (2004).","journal-title":"Gastroenterology"},{"key":"10198_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/hep.510280132","volume":"28","author":"S Zeuzem","year":"1998","unstructured":"Zeuzem, S. et al. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover. Hepatology 28, 245\u2013252 (1998).","journal-title":"Hepatology"},{"key":"10198_CR33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1542\/peds.72.5.613","volume":"72","author":"LH Taber","year":"1983","unstructured":"Taber, L. H. et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 72, 613\u2013618 (1983).","journal-title":"Pediatrics"},{"key":"10198_CR34","doi-asserted-by":"publisher","first-page":"S750","DOI":"10.1093\/clinids\/11.Supplement_4.S750","volume":"11","author":"JW Huggins","year":"1989","unstructured":"Huggins, J. W. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Reviews of Infectious Diseases 11, S750\u2013S761 (1989).","journal-title":"Reviews of Infectious Diseases"},{"key":"10198_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/153567601101600203","volume":"16","author":"JM Rusnak","year":"2011","unstructured":"Rusnak, J. M. Experience with ribavirin for treatment and postexposure prophylaxis of hemorrhagic fever viruses: Crimean Congo hemorrhagic fever, Lassa fever, and hantaviruses. Applied Biosafety 16, 67\u201387 (2011).","journal-title":"Applied Biosafety"},{"key":"10198_CR36","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1128\/AAC.11.6.1069","volume":"11","author":"R Berendt","year":"1977","unstructured":"Berendt, R., Walker, J. S., Dominik, J. W. & Stephen, E. L. Response of influenza virus-infected mice to selected doses of ribavirin administered intraperitoneally or by aerosol. Antimicrobial Agents and Chemotherapy 11, 1069\u20131070 (1977).","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10198_CR37","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.4049\/jimmunol.160.7.3487","volume":"160","author":"Q Ning","year":"1998","unstructured":"Ning, Q. et al. Ribavirin inhibits viral-induced macrophage production of tnf, il-1, the procoagulant fgl2 prothrombinase and preserves th1 cytokine production but inhibits th2 cytokine response. The Journal of Immunology 160, 3487\u20133493 (1998).","journal-title":"The Journal of Immunology"},{"key":"10198_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.23985","volume":"53","author":"E Thomas","year":"2011","unstructured":"Thomas, E. et al. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis c virus cell culture models. Hepatology 53, 32\u201341 (2011).","journal-title":"Hepatology"},{"key":"10198_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1128\/AAC.22.1.108","volume":"22","author":"CN Powers","year":"1982","unstructured":"Powers, C. N., Peavy, D. L. & Knight, V. Selective inhibition of functional lymphocyte subpopulations by ribavirin. Antimicrobial Agents and Chemotherapy 22, 108\u2013114 (1982).","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10198_CR40","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/095632020101200602","volume":"12","author":"DF Smee","year":"2001","unstructured":"Smee, D. F., Bray, M. & Huggins, J. W. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antiviral Chemistry & Chemotherapy 12, 327\u2013335 (2001).","journal-title":"Antiviral Chemistry & Chemotherapy"},{"key":"10198_CR41","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00418-009-0577-1","volume":"131","author":"JL Baratta","year":"2009","unstructured":"Baratta, J. L. et al. Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine structural analysis. Histochem. Cell Biol. 131, 713\u2013726 (2009).","journal-title":"Histochem. Cell Biol."},{"key":"10198_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-205","volume":"8","author":"LE Hensley","year":"2011","unstructured":"Hensley, L. E. et al. Pathogenesis of lassa fever in cynomolgus macaques. Virology Journal 8, 205 (2011).","journal-title":"Virology Journal"},{"key":"10198_CR43","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.4049\/jimmunol.172.5.2861","volume":"172","author":"S Baize","year":"2004","unstructured":"Baize, S. et al. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. The Journal of Immunology 172, 2861\u20132869 (2004).","journal-title":"The Journal of Immunology"},{"key":"10198_CR44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.antiviral.2015.08.015","volume":"123","author":"V Madelain","year":"2015","unstructured":"Madelain, V. et al. Ebola virus dynamics in mice treated with favipiravir. Antiviral Research 123, 70\u201377 (2015).","journal-title":"Antiviral Research"},{"key":"10198_CR45","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.3390\/v4112766","volume":"4","author":"M Russier","year":"2012","unstructured":"Russier, M., Pannetier, D. & Baize, S. Immune responses and lassa virus infection. Viruses 4, 2766\u20132785 (2012).","journal-title":"Viruses"},{"key":"10198_CR46","doi-asserted-by":"publisher","first-page":"22124","DOI":"10.1074\/jbc.M400908200","volume":"279","author":"I Bougie","year":"2004","unstructured":"Bougie, I. & Bisaillon, M. The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. Journal of Biological Chemistry 279, 22124\u201322130 (2004).","journal-title":"Journal of Biological Chemistry"},{"key":"10198_CR47","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/0006-291X(79)91853-9","volume":"89","author":"BB Goswami","year":"1979","unstructured":"Goswami, B. B., Borek, E., Sharma, O. K., Fujitaki, J. & Smith, R. A. The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochemical and biophysical research communications 89, 830\u2013836 (1979).","journal-title":"Biochemical and biophysical research communications"},{"key":"10198_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000836","volume":"6","author":"L Flatz","year":"2010","unstructured":"Flatz, L. et al. T cell-dependence of lassa fever pathogenesis. PLoS Pathog 6, e1000836 (2010).","journal-title":"PLoS Pathog"},{"key":"10198_CR49","doi-asserted-by":"crossref","unstructured":"Racanelli, V. & Rehermann, B. The liver as an immunological organ. Hepatology 43 (2006).","DOI":"10.1002\/hep.21060"},{"key":"10198_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1371\/journal.pcbi.1003730","volume":"10","author":"SM Ciupe","year":"2014","unstructured":"Ciupe, S. M., Ribeiro, R. M. & Perelson, A. S. Antibody responses during hepatitis B viral infection. PLoS Computational Biology 10, 7\u2013e1003730 (2014).","journal-title":"PLoS Computational Biology"},{"key":"10198_CR51","unstructured":"R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria http:\/\/www.R-project.org. ISBN 3-900051-07-0 (2006)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10198-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10198-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10198-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T16:23:17Z","timestamp":1692980597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-10198-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,15]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["10198"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-10198-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,15]]},"assertion":[{"value":"28 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11693"}}